Literature DB >> 24838613

Advances in the management of central nervous system germ cell tumors.

Nathan E Millard1, Ira J Dunkel.   

Abstract

Intracranial germ cell tumors represent a relatively small portion of pediatric central nervous system tumors, with a reported incidence ranging from 3.6% in North America to 15.3% in parts of Asia. They are known to arise in midline locations, most frequently the pineal gland and suprasellar regions, and affect males twice to three times more frequently than females, especially in the case of pineal-region tumors. The median age of diagnosis is 10-12 years. The treatment of intracranial germ cells tumors is complicated by their relative rarity, histologic heterogeneity, and a lack of widespread consensus on their optimal management. Despite these challenges, important progress continues to be made, with a move toward multicenter and international collaborative efforts that offer potential for clinical advancements. This review focuses on recent developments in the management of intracranial germ cell tumors, including updates in diagnosis, surveillance, biology, treatment, and outcomes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24838613     DOI: 10.1007/s11912-014-0393-1

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.945


  29 in total

1.  Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases.

Authors:  M Matsutani; K Sano; K Takakura; T Fujimaki; O Nakamura; N Funata; T Seto
Journal:  J Neurosurg       Date:  1997-03       Impact factor: 5.115

2.  Bifocal germ cell tumors.

Authors:  Frederick A Boop
Journal:  J Neurosurg Pediatr       Date:  2012-11-30       Impact factor: 2.375

Review 3.  The role of myeloablative chemotherapy with autologous hematopoietic cell rescue in central nervous system germ cell tumors.

Authors:  Eric Bouffet
Journal:  Pediatr Blood Cancer       Date:  2010-04       Impact factor: 3.167

4.  CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome.

Authors:  Hiroyuki Ogino; Yuta Shibamoto; Tsuyoshi Takanaka; Kazunori Suzuki; Shun-Ichi Ishihara; Tetsuya Yamada; Chikao Sugie; Yoshihito Nomoto; Mikio Mimura
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-01       Impact factor: 7.038

5.  Intensive chemotherapy followed by reduced-dose radiotherapy for biopsy-proven CNS germinoma with elevated beta-human chorionic gonadotropin.

Authors:  Do Hoon Lim; Keon Hee Yoo; Na Hee Lee; Soo Hyun Lee; Ki Woong Sung; Hong Hoe Koo; Ji Hye Kim; Yeon-Lim Suh; Yoo Sook Joung; Hyung Jin Shin
Journal:  J Neurooncol       Date:  2014-02-01       Impact factor: 4.130

6.  Pattern of relapse and outcome of non-metastatic germinoma patients treated with chemotherapy and limited field radiation: the SFOP experience.

Authors:  Claire Alapetite; Herve Brisse; Catherine Patte; Marie Anne Raquin; Genevieve Gaboriaud; Christian Carrie; Jean Louis Habrand; Philippe Thiesse; Jean Claude Cuilliere; Valerie Bernier; M Ben-Hassel; Didier Frappaz; Marie Christine Baranzelli; Eric Bouffet
Journal:  Neuro Oncol       Date:  2010-08-17       Impact factor: 12.300

Review 7.  Pediatric central nervous system germ cell tumors: a review.

Authors:  Maria E Echevarría; Jason Fangusaro; Stewart Goldman
Journal:  Oncologist       Date:  2008-06

8.  Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study.

Authors:  Nasjla Saba da Silva; Andrea M Cappellano; Blanca Diez; Sergio Cavalheiro; Sharon Gardner; Jeffrey Wisoff; Stewart Kellie; Robert Parker; James Garvin; Jonathan Finlay
Journal:  Pediatr Blood Cancer       Date:  2010-03       Impact factor: 3.167

9.  SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease.

Authors:  Gabriele Calaminus; Rolf Kortmann; Jennifer Worch; James C Nicholson; Claire Alapetite; Maria Luisa Garrè; Catherine Patte; Umberto Ricardi; Frank Saran; Didier Frappaz
Journal:  Neuro Oncol       Date:  2013-03-03       Impact factor: 12.300

10.  Highlights from the Third International Central Nervous System Germ Cell Tumour symposium: laying the foundations for future consensus.

Authors:  Matthew J Murray; Gail Horan; Stephen Lowis; James C Nicholson
Journal:  Ecancermedicalscience       Date:  2013-07-17
View more
  5 in total

1.  Clinical features, radiologic findings, and treatment of pediatric germ cell tumors involving the basal ganglia and thalamus: a retrospective series of 15 cases at a single center.

Authors:  Mengmeng Wang; Peizhi Zhou; Shizhen Zhang; Xueyou Liu; Liang Lv; Zeming Wang; Feng Ye; Yan Ju; Shu Jiang
Journal:  Childs Nerv Syst       Date:  2017-10-24       Impact factor: 1.475

2.  Basal Ganglia Germ Cell Tumors With or Without Sellar Involvement: A Long-Term Follow-Up in a Single Medical Center and a Systematic Literature Review.

Authors:  Yi Zhang; Li Wang; Wenbin Ma; Hui Pan; Renzhi Wang; Huijuan Zhu; Yong Yao
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-10       Impact factor: 5.555

3.  Epidemiology, Management, and Long-Term Survival Outcomes of Intracranial Typical Site Germinomas: An Analysis of the Surveillance, Epidemiology, and End-Results (SEER) Database.

Authors:  Wenqiang Che; Yujiao Wang; Yanmin Zhou; Xiangyu Wang; Jun Lyu
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

4.  A Case of Nongerminomatous Germ Cell Tumor with Fulminant Course Concomitant Leptomeningeal Metastasis.

Authors:  Youn-Beom Jeong; Kyu-Chang Wang; Ji Hoon Phi; Ji Yeoun Lee; Jung-Eun Cheon; Hyoung Jin Kang; Il Han Kim; Seung-Ki Kim
Journal:  Brain Tumor Res Treat       Date:  2016-04-29

Review 5.  Germ-cell tumors of the central nervous system in Peking Union Medical College Hospital: A 20-year clinicopathologic review.

Authors:  Zhen Huo
Journal:  Chin Med J (Engl)       Date:  2020-01-20       Impact factor: 2.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.